Chris Molloy has a 30-year international board and executive career across a unique range of life sciences R&D disciplines. He began in preclinical science and research management at Glaxo, where he was closely involved with the industrialisation of high throughput discovery, combining robotics, informatics and manufacturing theory. He moved to Asia as COO of MerLion Pharmaceuticals, a Singaporean natural products biotech that was developed into an award-winning multinational anti-infectives R&D company. Chris then ran corporate development for the global informatics firm, idbs – now part of the Danaher group. During Chris’ tenure idbs won a Queens Award for Enterprise, was a Fast-track 100 company, and the first UK firm to develop a stratified medicine software platform using real-world health data, co-investing alongside the Technology Strategy Board (now Innovate UK).
Chris spent three years as CEO of the RSA Group, the global life science executive search specialist, where he helped build high-value leadership teams in pharma, biotech, digital health and academia. In 2016 Chris became the founding CEO of the Medicines Discovery Catapult – the national research technology facility supporting the sector by industrialising and driving the adoption of new R&D techniques for discovering medicines. The Catapult has also created a national network of contract research, improved access to ethically consented bio-samples and health data, and deployed a ‘syndicated’ model for multiparty international collaborations that puts patient need – and their research charities – at the heart of modern drug discovery.
Chris is the non-executive chairman of Exploristics Ltd and NorthWest EHealth: two private UK tech companies using Real World healthcare data to improve clinical development. He chairs the IP Advisory Committee for the Association of Medical Research Charities and the Industry Advisory Board for Manchester’s Biomedical Research Centre & Health Innovation Manchester. Chris holds US and EU patents in HIV drug discovery; he is a Member of the Institute of Cancer Research and holds an honorary chair at the University of Manchester.